Skip to main content
Rural Health Information Hub

Rural Pharmacy and Prescription Drugs – Resources

Selected recent or important resources focusing on Rural Pharmacy and Prescription Drugs.

The 340B Drug Pricing Program: A Small Part of the Prescription Drug Market, Delivering Large Benefits to Patients and Communities
Analyzes impacts of the 340B Drug Pricing Program on access, hospital finance, drug companies, and public expenditures. Discusses how the 340B program is shaped by legislation, policy, finance, prescribing patterns, and market influences. Highlights rural and underserved communities throughout.
Date: 03/2024
Type: Document
Sponsoring organization: American Hospital Association
view details
Generic Drug Utilization and Spending Among Medicare Part D Enrollees in 2022
Issue brief on prescriptions for generic drugs filled by Medicare Part D enrollees using 2022 Part D prescription drug event (PDE) data. Covers commonly used prescription drugs, costs, and conditions treated, and includes data breakdowns by plan type, race and ethnicity, and level of rurality throughout. Discusses formulary design to improve access by promoting affordability and reducing confusion among enrollees.
Author(s): Yevgeniy Feyman, Bisma Sayed, Kenneth Finegold, et al.
Date: 03/2024
Type: Document
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Inflation Reduction Act Research Series: Projected Impacts for Rural Medicare Enrollees
Provides an overview of how the Inflation Reduction Act (IRA) is intended to improve prescription drug affordability for Medicare enrollees. Describes Medicare enrollment in rural areas and rural residents' health status and access to care. Outlines the projected impact of drug-related IRA provisions for rural Medicare beneficiaries, including the expansion of financial assistance through the low-income subsidy program, out-of-pocket spending caps for insulin, changes in Part D benefit design, and more.
Date: 03/2024
Type: Document
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
What Does Pharmacy Access Look like in Your Area?
Interactive map showing the number of pharmacies and pharmacies per 1,000 people at the state and county level. Includes the option to view race and ethnicity data at the county level for Black, Hispanic, and White residents.
Date: 02/2024
Type: Map/Mapping System
Sponsoring organization: The Associated Press
view details
Hearing on Examining Chronic Drug Shortages in the United States
Congressional hearing in the U.S. House of Representatives Ways & Means Committee discussing pharmaceutical drug shortages. Discusses cancer care, healthcare quality, the 340B program, supply and demand, reimbursement, and other policy measures. Witnesses include Dr. Stephen Schleicher discussing rural concerns. Captions available in video player.
Additional links: Dr. Stephen Schleicher Testimony
Date: 02/2024
Type: Video/Multimedia
Sponsoring organization: House Ways and Means Committee
view details
Testing the Feasibility of the QuitAid Smoking Cessation Intervention in a Randomized Factorial Design in an Independent, Rural Community Pharmacy
Examines a pharmacist-delivered smoking cessation intervention in rural Appalachia. Analyzes an ask-advise-connect model conducted with 24 adult smokers between September and November 2021, observing recruitment, retention, treatment adherence, and fidelity. Includes data on participant demographics, participant satisfaction, and pharmacist perceptions.
Author(s): Melissa A. Little, Taylor Reid, Matthew Moncrief, et al.
Citation: Pilot and Feasibility Studies, 10(41)
Date: 02/2024
Type: Document
view details
Medicare Enrollees and the Part D Drug Benefit: Improving Financial Protection through the Low- Income Subsidy
Provides an overview of the Medicare Part D Low-Income Subsidy (LIS) program, which covers some or all Part D drug costs. Presents estimates of number of Medicare Part D enrollees who received LIS in 2020 and their characteristics, as well as Medicare beneficiaries who did and did not have prescription drug coverage but who appear to be eligible for LIS based on income and resources. Compares Medicare enrollees demographic, financial, health status, and healthcare utilization characteristics, including rurality.
Author(s): Yevgeniy Feyman, Joel Ruhter, Kenneth Finegold, et al.
Date: 02/2024
Type: Document
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
340B Discount Drug Program Reform Policy Principles
Policy position paper on the 340B program. Explores ways in which the program benefits rural health systems and patients, and the impact of restrictions by drug manufacturers on rural safety net providers .
Date: 2024
Type: Document
Sponsoring organization: National Rural Health Association
view details
Addressing COVID-19 Vaccine Hesitancy in Rural Community Pharmacies: A Protocol for a Stepped Wedge Randomized Clinical Trial
Evaluates implementation strategies of rural-located pharmacies looking to address COVID-19 vaccine hesitancy in their communities. Describes how the study will examine intervention fidelity, effectiveness, feasibility, acceptability, adoption, reach, and cost.
Author(s): Geoffrey Curran, Cynthia Mosley, Abigail Gamble, et al.
Citation: Implementation Science, 18, 72
Date: 12/2023
Type: Document
view details
Hospital Outpatient Prospective Payment System (OPPS): Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-2022 Final Rule (CMS 1793-F)
Fact sheet providing an overview of the Centers for Medicare & Medicaid Services (CMS) final rule describing the agency's actions to remedy payment cuts to certain hospitals that participate in the 340B Drug Pricing Program from 2018-2022 that were declared unlawful by the Supreme Court's decision in American Hospital Association v. Becerra, 142 S. Ct. 1896 (2022). Details the one-time lump sum payments to affected 340B covered entities to what they would have been paid had the 340B payment cuts not been applied, as well as a 0.5% payment reduction on future non-drug item and service payments to maintain budget neutrality beginning in calendar year 2026.
Date: 11/2023
Type: Document
Sponsoring organization: Centers for Medicare and Medicaid Services
view details

Additional resources are available related to this guide. See the full list of resources by topic for:


Last Updated: 11/7/2024